Benitec Biopharma (BNTC) Stock Overview

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC Stock Information

Symbol

BNTC

Address

3940 Trust WayHayward, CA 94545United States

Founded

Trading hours

Website

https://benitec.com

Country

🇺🇸 United States

Phone Number

510 780 0819

Benitec Biopharma (BNTC) Price Chart

Benitec Biopharma Overview: Key Details and Summary

Stock data	2023	Change
Price	$9.24	N/A
Market Cap	$753.63K	N/A
Shares Outstanding	81.52K	188.30%
Employees	17.00	N/A
Shareholder Equity	202.00K	-92.99%

Valuation	2023	Change
P/E Ratio	-0.04	N/A
P/S Ratio	10.05	N/A
P/B Ratio	3.73	N/A

Growth	2023	Change
Return on Equity	-96.8416	N/A

Earnings	2023	Change
Revenue	$75.00K	N/A
Earnings	-$19.56M	N/A
EPS	-240.04	N/A
Earnings Yield	-25.96	N/A
Gross Margin	1.00	N/A
Operating Margin	-254.41	N/A
Net income margin	-260.83	N/A

Financial Strength	2023	Change
Total Assets	$4.46M	N/A
Total Debt	$559.00K	N/A
Cash on Hand	$2.48M	N/A
Debt to Equity	$21.10	1867.24%
Cash to Debt	$4.43	-11.53%
Current Ratio	0.9374	-50.76%